Sign In
14 Nov 2017 11:30
REDX PHARMA PLC
("Redx" or "the Company")
Â
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES
Â
Alderley Park, November 14 2017-Â Redx Pharma (AIM:REDX), the drug discovery and development company, announces that is has been notified that Iain Ross, Executive Chairman, has today acquired 348,000 Redx ordinary shares at a price of 18.036 pence per share. Following this, Mr Ross will hold 348,000 ordinary shares in the Company, representing 0.28 per cent. of the issued share capital.
Â
Mr Ross purchased the shares through his self-invested personal pension (SIPP) and the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
Â
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Iain Ross |
2 | Reason for the notification | |
a) | Position/status | Executive Chairman |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Redx Pharma plc |
b) | LEI | 213800HMS4EBXO589Y37 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 1 pence  ISIN: GB00BSNB6S51 |
b) | Nature of the transaction | Purchase of shares through self-invested personal pension (SIPP) |
c) | Price(s) and volume(s) | 348,000 ordinary shares at a price of 18.036 pence per share |
d) | Aggregated information - Aggregated volume - Price  | N/A |
e) | Date of the transaction | 14 November 2017Â |
f) | Place of the transaction | London Stock Exchange, AIM (XLON) |
Â
For further information, please contact:
Â
Redx Pharma Plc | T: +44 1625 469 918 |
Iain Ross, Executive Chairman | Â |
Cantor Fitzgerald Europe (Nominated Advisor & Broker) | Â T: +44 20 7894 7000 |
Phil Davies | Â |
 |  |
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes SpĂĄng/ Chris Lee/ David Wilson | Â |
 |  |
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Stephanie Cuthbert | Â |
Â
About Redx Pharma Plc
Â
Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of oncology and fibrosis that address significant unmet medical need. Redx has a significant in-house discovery team with proven world-class chemistry capabilities.
Â
Â
Follow the stocks
